A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2019
Price : $35 *
At a glance
- Drugs Afatinib (Primary) ; Monalizumab (Primary) ; Palbociclib (Primary) ; Bleomycin; Bleomycin; Bleomycin; Docetaxel; Fluorouracil; Gemcitabine; Methotrexate; Mitomycin; Paclitaxel
- Indications Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms UPSTREAM
- 20 Jun 2019 Planned number of patients changed from 205 to 340.
- 12 Nov 2018 According to Innate Pharma media release, data from thi study will be presented at SITC 2018 Annual Meeting .
- 16 Oct 2018 According to Innate Pharma media release, data from thi study will be presented at the ESMO 2018 Congress.